🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07611448
Enrolling by invitation Observational

Blastocyst AI Assisted Morphokinetics in ART

NCT07611448 · tracked via the Priya Life Science USA tracker
Sponsor
Viable Biosciences
Phase
Observational
Started
2026-03-05
Last updated
2026-05-28

Condition(s) studied

Infertility Assisted Reproductive TechnologyInfertility (IVF Patients)

Study summary

The goal of this observational study is to learn if embryo characteristics obtained via the recording of real-time embryo activity via 30-seconds video capture (e.g.: Embryo Morphokinetics) can correlate with known embryo outcome in patients receiving In-Vitro Fertilization Treatment (IVF).

Current Embryo morphology is performed with direct observation of embryo characteristics under the microscope. The observer will follow embryo grading standards based on embryo symmetry, development stage and growth pattern based on day of culture, presence of defined embryo characteristics with definition of viability to transfer into the uterus, cryopreserve for future use or discard.

Today, the final embryo outcome can be correlated with the subjective embryo grading performed by the embryologist to evaluate how precise is the viability assessment of embryo characteristics and potential.

This observational study attempts to create enough data to evaluate if real-time embryo morphokinetics can correlate with known outcomes. Patients participating in this study will not obtain any benefit from the recording of their embryos. They'll continue with their treatment according to the medical provider decision. Embryos will be selected using standard of care practice including:

Transfer into the uterus. Cryopreservation. Biopsy for pre-implantation genetic testing and cryopreservation. Discard. The data obtained from this study will be analyzed to generate hypothesis and potentially design a prospective study where this tool can be used to aid in the embryo grading and selection process in comparison with standard of care.

The study includes patients undergoing Assisted Reproductive Technologies (ART) including IVF, Intracytoplasmic Sperm Injection (ICSI), Frozen-Thawed Embryo Transfer including or not Embryos previously analyzed genetically. This includes embryos already defined as viable (genetically normal) or embryos to be discarded (genetically abnormal).

What is Embryo Morphokinetics? Embryos are in constant movement with cellular activity invisible to the naked eye. Capturing a real-time video can convert that cellular movement and activity into pixels. Those pixels can be followed, and certain patterns can be observed and created. With the use of Artificial Intelligence (AI) those patterns can be identified, labelled, and analyzed to potentially be correlated with embryo outcome. It has been demonstrated, in the animal field, that embryos with certain morphokinetics patterns do not implant inside the uterus therefore not achieving a pregnancy. Also, embryos with high activity may be associated with genetic abnormality.

In this study the following comparisons will be performed.

Embryo Morphokinetics at the Blastocyst stage including:

Blastocyst morphokinetics before cryopreservation and after thawing. Blastocyst morphokinetics before and after trophectoderm biopsy. Blastocyst morphokinetics in euploid embryos before transfer. Blastocyst morphokinetics in aneuploid embryos before discard.

* Primary hypothesis: Blastocyst morphokinetics correlate with Pregnancy outcome
* Secondary hypothesis: Blastocyst morphokinetics correlates with embryo recovery after thawing and after biopsy.
* Tertiary hypothesis: Blastocyst morphokinetics correlates with know genetic diagnosis (euploid or aneuploid)

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Signed Inform Consent * Ages between 18 and 45 years * Patients using own or donated eggs * Patients undergoing assisted reproduction procedures (ICSI with Embryo Transfer, Frozen Embryo Transfers with or without PGT-A receiving a single embryo transfer. * Patients with at least one embryo at the blastocyst stage on day 5, day 6 or day 7 of embryo development. * Patients using a surrogate carrier for the embryo transfer procedure. * Patients with Abnormal Embryos after PGT-A to be discarded. * Patients with Euploid Embryos after PGT-A to be discarded Exclusion Criteria: * Absence of viable embryos at the blastocyst stage. * Any uterine abnormalities that could affect embryo implantation.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Women's Specialty & Fertility Center Clovis California

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07611448 on ClinicalTrials.gov ↗ ← All trials in the USA